Bispecific Antibody Therapeutics Industry Report by 2030 | Roots Analysis

Business

Bispecific antibody therapeutics represent a transformative approach to modern treatment; over the years, this upcoming class of ‘two-target’ artificially engineered drugs have generated significant enthusiasm within the medical science community

Roots Analysis is pleased to announce the publication of its recent study, titled, “Bispecific Antibody Therapeutics Market, 2021-2030.”

The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. The study features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape of drug developers engaged in the development of bispecific antibody therapeutics.
  • A comprehensive analysis of novel technology platforms that are either currently available or being developed for the generation of bispecific antibody therapeutics.
  • Detailed profiles of marketed and clinical stage (phase II and phase III) bispecific antibody therapeutics.
  • Key takeaways from the bispecific antibody therapeutics pipeline.
  • An analysis of the initiatives of big biopharma players engaged in this domain.
  • An analysis of recent partnerships and collaboration agreements inked in bispecific antibody therapeutics domain.
  • A review on the key steps involved and challenges associated with the manufacturing of bispecific antibodies.
  • A clinical trial analysis of ongoing and planned studies related to bispecific antibody therapeutics.
  • A review of the key promotional strategies that have been adopted by the developers of the marketed bispecific antibodies.
  • A discussion on important, industry-specific trends, key market drivers and challenges, under a SWOT framework.

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

Target Disease Indication

  • Autoimmune Disorders
  • Eye Disorders
  • Genetic Disorders
  • Hematological Malignancies
  • Infectious Diseases
  • Inflammatory Disorders
  • Skin Disorders

Mechanism of Action

  • Cytokines Retargeting / Neutralization
  • Dual Ligands Blocking
  • T-cell Retargeting / Activation
  • Others

Target Antigens

  • CD3 x CD19
  • CD30 x CD16A
  • Factor IXa x Factor X
  • IL-1α x IL-1β
  • IL-13 x IL-4
  • IL-17A x Albumin
  • IL-17A x IL-17F
  • Psl x PcrV
  • TNF-α x HAS
  • VEGF-A x ANG2
  • Others

Antibody Format

  • Asymmetric
  • Fragments
  • Symmetric
  • Others

Key Geographical Region

  • North America
  • Europe
  • Asia-Pacific

Transcripts of interviews held with the following senior level representatives of stakeholder companies:

  • Martin Steiner (Chief Executive Officer, Synimmune)
  • Ludger Große-Hovest (Chief Scientific Officer, Synimmune)
  • Jane Dancer (Chief Business Officer, F-Star)
  • Siobhan Pomeroy (Senior Director, Business Development, Cytom X)
  • Yinjue Wang (Associate Director, Process Development, Innovent Biologics)

Key companies covered in the report

  • Amgen
  • Ablynx
  • AbbVie
  • Affibody
  • Affimed
  • Alphamab
  • AstraZeneca
  • Avillion
  • Chugai Pharmaceuticals
  • Eddingpharm
  • GSK
  • Merck
  • Merus
  • Roche
  • Regeneron Pharmaceuticals
  • Taisho Pharmaceuticals
  • Zymeworks   

Chapter Outlines

Chapter 2 provides an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the market for bispecific antibody therapeutics and its likely evolution in the mid to long term.

Chapter 3 provides a general overview of antibodies, including their historical background, structure, and the different types of antibodies available, along with their mechanisms of action. In addition, the chapter highlights the evolution of antibody-based therapeutics over the last few years. It also features a discussion on bispecific antibodies, elaborating on the different bispecific formats that are currently available, mechanisms of action of various products / product candidates and their applications.

Chapter 4 provides information on over 300 bispecific antibody drug candidates that are either approved or in different stages of development (clinical and preclinical / discovery). It features an analysis of drug developers on basis of various parameters, such as year of establishment, company size and geographical location, phase of development (marketed, clinical, and preclinical / discovery stage) of the pipeline molecules, target antigens, type of antibody format (symmetric antibody format, asymmetric antibody format, fragments and others), mechanism of action, target disease indication(s), therapeutic area, broader disease segment (oncology / non-oncology), route of administration and patient segment.

Chapter 5 includes a list of innovative technology platforms that are either currently available, or being developed by various firms, for the generation of bispecific antibody therapeutics, along with detailed profiles of key technologies. Each profile contains details on the technology, including the pipeline molecules being developed using the technology, its advantages and partnerships established related to the technology. The chapter also includes an insightful competitiveness analysis, featuring a three-dimensional bubble representation that highlights the key technologies that are being used for the development of bispecific antibodies, taking into consideration early stage (discovery, preclinical, IND and phase I) and late stage (phase II and above) the development activity based on the technology (in terms of the number of drugs across different phases of development) and the size of the developer company. In addition, it features a schematic world map representation, highlighting the geographical locations of technology developers, along with the symbol representation for drug portfolio for each technology.

Leave a Reply

Your email address will not be published. Required fields are marked *